Guardant Health (GH) issued the following statement regarding the favorable recommendation by U.S. District Court Magistrate Judge Christopher Burke that nearly all claims brought by Illumina (ILMN) against Guardant Health in a lawsuit filed on March 17, 2022, be dismissed: "We are pleased with Judge Burke’s recommendation that nearly all of Illumina’s claims be dismissed as filed. We continue to believe that Illumina has no basis for challenging the ownership of our patents and that this lawsuit is nothing more than an attempt to impede our mission to improve cancer care and save patients’ lives."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GH:
- FDA okays Guardant360 as companion diagnostic in patients with ESR1 mutations
- Sell these stocks now, proven algorithm says
- Guardant Health partners with The Royal Marsden NHS Foundation for TRACC study
- Guardant Health call volume above normal and directionally bullish
- Guardant Health sees FY22 revenue $447M-$450M, consensus $445.24M